Top Stock Reports for NVIDIA, Mastercard & AbbVie
View original at finance.yahoo.comTop Stock Reports for NVIDIA, Mastercard & AbbVie Tuesday, May 12, 2026 The Zacks Research Daily presents the best research output of our analyst team…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
NVIDIA has collaborations with more than 320 automakers and tier-one suppliers likely to advance its presence in the autonomous vehicle space
60% confidenceNVIDIA is benefiting from the strong growth of artificial intelligence and high-performance accelerated computing; growing demand for generative AI and large language models using GPUs based on Hopper and Blackwell architectures is aiding data center revenues
60% confidenceRising costs associated with producing more complex AI systems will hurt NVIDIA's margins
60% confidenceThe U.S.-China tech war and rising competition from AMD remain major concerns for NVIDIA
60% confidenceMastercard's rebates and incentives are rising with new and renewed deals; geopolitical disruption is weighing on cross-border travel
60% confidenceMastercard's scale and brand strength continue to support steady payment network growth, helped by stable consumer and business spending and higher transaction activity
60% confidenceAbbVie successfully navigated Humira's loss of exclusivity by launching Skyrizi and Rinvoq, which should support top-line growth in the next few years
60% confidenceAbbVie faces headwinds from Humira LOE impact, slowing oncology sales and continued macro headwinds for its Aesthetics segment
60% confidenceA limited supply of Blackwell GPUs may hinder NVIDIA's ability to meet demand
60% confidencePrecipio's story remains execution-sensitive due to liquidity constraints and product-margin volatility; valuation implies cautious market sentiment despite improving profitability
60% confidenceAbbVie expects important data readouts, regulatory submissions and approvals throughout 2026 from its robust pipeline
60% confidencePrecipio's investment thesis is centered on the scalability of its pathology platform and integrated lab-and-diagnostics model; core pathology business demonstrates operating leverage supporting margin expansion
60% confidenceWaterstone Financial maintains strong capital and liquidity with risk-based capital above 20% and substantial unused FHLB borrowing capacity
60% confidenceMastercard's valuation remains elevated, supporting a Neutral view on the stock
60% confidenceWaterstone Financial delivered a strong earnings rebound in Q1 2026; higher asset yields and easing funding costs expanded net interest margin to 2.97% from 2.47%, driving EPS growth
60% confidenceWaterstone Financial's mortgage banking returned to profitability, supported by a 31% increase in originations and a sharp refinancing recovery
60% confidenceWaterstone Financial shares trade below peer valuation levels at 11.05X earnings and 0.95X book value
60% confidenceMastercard management expects operating expenses to keep growing as it funds safety, security, digital and B2B initiatives
60% confidence
Cited in these Via News reports
- Fed Leaderless at 5%: Global Bond Markets Price In Permanent Inflation →
- Nobel Economist Acemoglu: AI's Productivity Boost Will Be 'Small'—A Problem for Markets Worldwide →
- Powell Out, Warsh In: Global Rate-Cut Dreams Die as US CPI Holds at 3.8% →
- Warsh Takes Fed Chair With U.S. CPI at 3.8% as ECB Eyes Hikes and Global Rates Stay Elevated →